These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 19195334

  • 1. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
    Yebra G, Holguín A.
    Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334
    [Abstract] [Full Text] [Related]

  • 2. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
    Seclén E, González Mdel M, Corral A, de Mendoza C, Soriano V, Poveda E.
    AIDS; 2010 Jan 28; 24(3):467-9. PubMed ID: 19996935
    [Abstract] [Full Text] [Related]

  • 3. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
    Malet I, Wirden M, Derache A, Simon A, Katlama C, Calvez V, Marcelin AG.
    AIDS; 2007 Apr 23; 21(7):871-3. PubMed ID: 17415044
    [Abstract] [Full Text] [Related]

  • 4. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.
    Antimicrob Agents Chemother; 2007 Oct 23; 51(10):3574-81. PubMed ID: 17638699
    [Abstract] [Full Text] [Related]

  • 5. Determinants of activity of the HIV-1 maturation inhibitor PA-457.
    Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.
    Virology; 2007 Oct 23; 356(1-2):217-24. PubMed ID: 16930665
    [Abstract] [Full Text] [Related]

  • 6. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
    Urano E, Timilsina U, Kaplan JA, Ablan S, Ghimire D, Pham P, Kuruppu N, Mandt R, Durell SR, Nitz TJ, Martin DE, Wild CT, Gaur R, Freed EO.
    J Virol; 2019 Mar 15; 93(6):. PubMed ID: 30567982
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F, Malet I, D'Arrigo R, Antinori A, Marcelin AG, Perno CF.
    AIDS Rev; 2009 Mar 15; 11(1):17-29. PubMed ID: 19290031
    [Abstract] [Full Text] [Related]

  • 9. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
    Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Nagashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO.
    J Virol; 2006 Nov 15; 80(22):10957-71. PubMed ID: 16956950
    [Abstract] [Full Text] [Related]

  • 10. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
    Holguín A, Suñe C, Hamy F, Soriano V, Klimkait T.
    J Clin Virol; 2006 Aug 15; 36(4):264-71. PubMed ID: 16765636
    [Abstract] [Full Text] [Related]

  • 11. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
    Yaotsè DA, Nicole V, Roch NF, Mireille PD, Eric D, Martine P.
    Infect Genet Evol; 2009 Jul 15; 9(4):646-52. PubMed ID: 19460333
    [Abstract] [Full Text] [Related]

  • 12. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.
    Verheyen J, Knops E, Kupfer B, Hamouda O, Somogyi S, Schuldenzucker U, Hoffmann D, Kaiser R, Pfister H, Kücherer C.
    J Infect; 2009 Jan 15; 58(1):61-7. PubMed ID: 19110315
    [Abstract] [Full Text] [Related]

  • 13. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
    Di Giambenedetto S, Zazzi M, Corsi P, Gonnelli A, Di Pietro M, Giacometti A, Almi P, Trezzi M, Boeri E, Gianotti N, Menzo S, Del Gobbo R, Francisci D, Nerli A, Galli L, De Luca A, Antiretroviral Resistance Cohort Analysis Study Group.
    Antivir Ther; 2009 Jan 15; 14(3):359-69. PubMed ID: 19474470
    [Abstract] [Full Text] [Related]

  • 14. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
    Verheyen J, Verhofstede C, Knops E, Vandekerckhove L, Fun A, Brunen D, Dauwe K, Wensing AM, Pfister H, Kaiser R, Nijhuis M.
    AIDS; 2010 Mar 13; 24(5):669-73. PubMed ID: 19926962
    [Abstract] [Full Text] [Related]

  • 15. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
    Martin DE, Salzwedel K, Allaway GP.
    Antivir Chem Chemother; 2008 Mar 13; 19(3):107-13. PubMed ID: 19024627
    [Abstract] [Full Text] [Related]

  • 16. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
    Santos AF, Abecasis AB, Vandamme AM, Camacho RJ, Soares MA.
    J Antimicrob Chemother; 2009 Mar 13; 63(3):593-9. PubMed ID: 19136678
    [Abstract] [Full Text] [Related]

  • 17. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid.
    Zhou J, Chen CH, Aiken C.
    Retrovirology; 2004 Jun 29; 1():15. PubMed ID: 15225375
    [Abstract] [Full Text] [Related]

  • 18. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
    Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP, Martin DE, Nitz TJ, Wild CT, Freed EO.
    Antimicrob Agents Chemother; 2016 Jan 29; 60(1):190-7. PubMed ID: 26482309
    [Abstract] [Full Text] [Related]

  • 19. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP, Queiroz BB, Stefani MM.
    J Clin Virol; 2009 Oct 29; 46(2):134-9. PubMed ID: 19682948
    [Abstract] [Full Text] [Related]

  • 20. A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
    Ghimire D, Kc Y, Timilsina U, Goel K, Nitz TJ, Wild CT, Gaur R.
    Retrovirology; 2021 Apr 09; 18(1):9. PubMed ID: 33836787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.